In addition, dual-targeted CAR T-cells (CD19/CD22, CD19/CD20) have shown promising activity in acute lymphoblastic leukemia (ALL), as well as B-cell malignancies [67,68,69]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.